Perceptive Advisors
Latest statistics and disclosures from Perceptive Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are FOLD, RETA, AMLX, CERE, MDGL, and represent 29.45% of Perceptive Advisors's stock portfolio.
- Added to shares of these 10 stocks: RETA (+$197M), OBIO (+$45M), SNY (+$42M), ACLX (+$38M), APLS (+$37M), IOVA (+$33M), NTRA (+$32M), CBAY (+$28M), PTGX (+$22M), IMVT (+$18M).
- Started 20 new stock positions in AVDL, TERN, Athenex, BLPH, SNY, VKTX, ADCT, PTGX, CELL, TCMD. OBIO, FUSN, BMEA, APLS, MIRM, XFOR, RETA, VIR, QTRX, XBI.
- Reduced shares in these 10 stocks: HZNP (-$109M), MDGL (-$92M), SRPT (-$54M), VRNA (-$43M), Albireo Pharma (-$38M), Cincor Pharma (-$32M), BLU (-$28M), MRTX (-$23M), SWTX (-$14M), RVNC (-$14M).
- Sold out of its positions in ACRS, ABOS, Albireo Pharma, Athenex, SAVA, Cincor Pharma, DICE, Isoplexis Corp, NVRO, PEN. PNT, PRCT, PRVA, RVNC, SCPH, HZNP.
- Perceptive Advisors was a net buyer of stock by $123M.
- Perceptive Advisors has $3.4B in assets under management (AUM), dropping by -4.89%.
- Central Index Key (CIK): 0001224962
Tip: Access up to 7 years of quarterly data
Positions held by Perceptive Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Perceptive Advisors
Perceptive Advisors holds 99 positions in its portfolio as reported in the March 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Amicus Therapeutics (FOLD) | 9.1 | $307M | 28M | 11.09 |
|
|
| Reata Pharmaceuticals Cl A (RETA) | 5.8 | $197M | NEW | 2.2M | 90.92 |
|
| Amylyx Pharmaceuticals (AMLX) | 5.2 | $177M | 6.0M | 29.34 |
|
|
| Cerevel Therapeutics Hldng I (CERE) | 4.7 | $159M | 6.5M | 24.39 |
|
|
| Madrigal Pharmaceuticals (MDGL) | 4.7 | $158M | -36% | 651k | 242.26 |
|
| Prometheus Biosciences (RXDX) | 4.0 | $137M | +4% | 1.3M | 107.32 |
|
| Arcellx Common Stock (ACLX) | 3.5 | $118M | +47% | 3.8M | 30.81 |
|
| Lianbio Sponsored Ads (LIAN) | 3.3 | $113M | 58M | 1.96 |
|
|
| Aldeyra Therapeutics (ALDX) | 3.3 | $113M | 11M | 9.93 |
|
|
| Iovance Biotherapeutics (IOVA) | 2.8 | $94M | +53% | 15M | 6.11 |
|
| Inhibrx (INBX) | 2.0 | $68M | +9% | 3.6M | 18.87 |
|
| Xenon Pharmaceuticals (XENE) | 1.9 | $66M | -4% | 1.8M | 35.79 |
|
| BioMarin Pharmaceutical (BMRN) | 1.9 | $65M | +32% | 673k | 97.24 |
|
| Treace Med Concepts (TMCI) | 1.8 | $62M | +25% | 2.4M | 25.19 |
|
| Nuvalent Inc-a (NUVL) | 1.8 | $60M | 2.3M | 26.09 |
|
|
| Mirati Therapeutics (MRTX) | 1.7 | $59M | -28% | 1.6M | 37.18 |
|
| Crinetics Pharmaceuticals In (CRNX) | 1.7 | $57M | -11% | 3.6M | 16.06 |
|
| Verona Pharma Sponsored Ads (VRNA) | 1.6 | $55M | -43% | 2.7M | 20.08 |
|
| Springworks Therapeutics (SWTX) | 1.6 | $54M | -20% | 2.1M | 25.74 |
|
| Health Sciences Acq Corp 2 (OBIO) | 1.3 | $45M | NEW | 2.3M | 19.57 |
|
| Miragen Therapeutics (VRDN) | 1.3 | $44M | +42% | 1.7M | 25.44 |
|
| Vaxcyte (PCVX) | 1.3 | $44M | 1.2M | 37.48 |
|
|
| Rapt Therapeutics (RAPT) | 1.2 | $42M | +27% | 2.3M | 18.35 |
|
| Sanofi Sponsored Adr (SNY) | 1.2 | $42M | NEW | 768k | 54.42 |
|
| Adma Biologics (ADMA) | 1.2 | $39M | 12M | 3.31 |
|
|
| Natera (NTRA) | 1.2 | $39M | +444% | 707k | 55.52 |
|
| Acrivon Therapeutics Common Stock (ACRV) | 1.1 | $38M | 3.0M | 12.69 |
|
|
| Apellis Pharmaceuticals (APLS) | 1.1 | $37M | NEW | 555k | 65.96 |
|
| Meiragtx Holdings (MGTX) | 1.1 | $36M | 7.0M | 5.17 |
|
|
| Sarepta Therapeutics (SRPT) | 1.1 | $36M | -59% | 261k | 137.83 |
|
| Bellus Health Com New (BLU) | 1.1 | $36M | -44% | 5.0M | 7.20 |
|
| Cymabay Therapeutics (CBAY) | 1.0 | $34M | +450% | 3.9M | 8.72 |
|
| Verrica Pharmaceuticals (VRCA) | 1.0 | $33M | 5.0M | 6.50 |
|
|
| Relay Therapeutics (RLAY) | 0.9 | $32M | 1.9M | 16.47 |
|
|
| Establishment Labs Holdings Ord (ESTA) | 0.9 | $32M | -6% | 468k | 67.74 |
|
| Bridgebio Pharma (BBIO) | 0.9 | $32M | +12% | 1.9M | 16.58 |
|
| Zymeworks Del (ZYME) | 0.9 | $31M | -25% | 3.4M | 9.04 |
|
| Astria Therapeutics (ATXS) | 0.9 | $29M | 2.2M | 13.30 |
|
|
| Nautilus Biotechnology (NAUT) | 0.7 | $25M | 9.1M | 2.77 |
|
|
| Cogent Biosciences (COGT) | 0.7 | $25M | -28% | 2.3M | 10.79 |
|
| Immatics SHS (IMTX) | 0.7 | $24M | 3.5M | 6.90 |
|
|
| Protagonist Therapeutics (PTGX) | 0.7 | $22M | NEW | 965k | 23.00 |
|
| Outset Med (OM) | 0.6 | $20M | 1.1M | 18.40 |
|
|
| Immunovant (IMVT) | 0.6 | $20M | +761% | 1.3M | 15.51 |
|
| Akero Therapeutics (AKRO) | 0.6 | $20M | +49% | 524k | 38.26 |
|
| Roivant Sciences SHS (ROIV) | 0.6 | $20M | +35% | 2.7M | 7.38 |
|
| Lyra Therapeutics (LYRA) | 0.5 | $18M | 9.1M | 2.01 |
|
|
| Solid Biosciences Com New (SLDB) | 0.5 | $17M | 3.5M | 4.74 |
|
|
| Tarsus Pharmaceuticals (TARS) | 0.5 | $16M | 1.3M | 12.57 |
|
|
| Terns Pharmaceuticals (TERN) | 0.5 | $16M | NEW | 1.4M | 11.84 |
|
| Vbi Vaccines Inc Cda Com New (VBIV) | 0.5 | $16M | 52M | 0.30 |
|
|
| Rocket Pharmaceuticals (RCKT) | 0.4 | $15M | -19% | 868k | 17.13 |
|
| Viking Therapeutics (VKTX) | 0.4 | $15M | NEW | 872k | 16.65 |
|
| Mirum Pharmaceuticals (MIRM) | 0.4 | $14M | NEW | 602k | 24.02 |
|
| Rain Therapeutics (RAIN) | 0.4 | $14M | -33% | 1.6M | 8.74 |
|
| CryoLife (AORT) | 0.4 | $14M | 1.1M | 13.10 |
|
|
| Axogen (AXGN) | 0.4 | $13M | 1.4M | 9.45 |
|
|
| Intuitive Surgical Com New (ISRG) | 0.4 | $13M | +25% | 50k | 255.47 |
|
| Iveric Bio (ISEE) | 0.4 | $12M | -14% | 500k | 24.33 |
|
| Athira Pharma (ATHA) | 0.4 | $12M | 4.8M | 2.50 |
|
|
| Cytek Biosciences (CTKB) | 0.3 | $12M | 1.3M | 9.19 |
|
|
| Prothena Corp SHS (PRTA) | 0.3 | $12M | 238k | 48.47 |
|
|
| Tactile Systems Technology, In (TCMD) | 0.3 | $11M | NEW | 640k | 16.42 |
|
| Fusion Pharmaceuticals (FUSN) | 0.3 | $10M | NEW | 2.8M | 3.77 |
|
| Larimar Therapeutics (LRMR) | 0.3 | $10M | -20% | 2.3M | 4.53 |
|
| Neurocrine Biosciences (NBIX) | 0.3 | $10M | 100k | 101.22 |
|
|
| Biomea Fusion (BMEA) | 0.3 | $10M | NEW | 325k | 31.01 |
|
| Morphic Hldg (MORF) | 0.3 | $9.7M | -29% | 257k | 37.64 |
|
| Caremax Com Cl A (CMAX) | 0.3 | $9.5M | +14% | 3.6M | 2.67 |
|
| Tyra Biosciences (TYRA) | 0.2 | $7.9M | 494k | 16.07 |
|
|
| Spdr Ser Tr S&p Biotech Put Option (XBI) | 0.2 | $7.6M | NEW | 100k | 76.21 |
|
| Bellerophon Therapeutics Com New (BLPH) | 0.2 | $7.3M | NEW | 930k | 7.89 |
|
| Hillevax (HLVX) | 0.2 | $6.7M | 406k | 16.53 |
|
|
| Cabaletta Bio (CABA) | 0.2 | $6.0M | +128% | 725k | 8.27 |
|
| Avadel Pharmaceuticals Sponsored Adr (AVDL) | 0.2 | $5.4M | NEW | 590k | 9.16 |
|
| Female Health (VERU) | 0.1 | $5.0M | -45% | 4.3M | 1.16 |
|
| Landos Biopharma (LABP) | 0.1 | $4.4M | 15M | 0.30 |
|
|
| Singular Genomics Systems In (OMIC) | 0.1 | $4.0M | 3.3M | 1.21 |
|
|
| X4 Pharmaceuticals (XFOR) | 0.1 | $4.0M | NEW | 4.5M | 0.87 |
|
| Somalogic Class A Com (SLGC) | 0.1 | $3.8M | 1.5M | 2.55 |
|
|
| Nanobiotix Sponsored Ads (NBTX) | 0.1 | $3.7M | 1.1M | 3.52 |
|
|
| Envveno Medical (NVNO) | 0.1 | $3.7M | 782k | 4.68 |
|
|
| Vir Biotechnology (VIR) | 0.1 | $3.3M | NEW | 142k | 23.27 |
|
| Harmony Biosciences Hldgs In (HRMY) | 0.1 | $3.3M | -75% | 100k | 32.65 |
|
| Adc Therapeutics Sa SHS (ADCT) | 0.1 | $2.9M | NEW | 1.5M | 1.95 |
|
| Berkeley Lts (CELL) | 0.1 | $2.9M | NEW | 2.5M | 1.16 |
|
| Kronos Bio (KRON) | 0.1 | $2.6M | 1.8M | 1.46 |
|
|
| Leap Therapeutics (LPTX) | 0.1 | $2.3M | 6.7M | 0.34 |
|
|
| Travere Therapeutics (TVTX) | 0.1 | $2.0M | 91k | 22.49 |
|
|
| Quanterix Ord (QTRX) | 0.0 | $1.5M | NEW | 130k | 11.27 |
|
| Dariohealth Corp Com New (DRIO) | 0.0 | $1.3M | -4% | 314k | 4.12 |
|
| Clover Health Investments Com Cl A (CLOV) | 0.0 | $1.3M | 1.5M | 0.85 |
|
|
| Athenex Com New | 0.0 | $1.0M | NEW | 777k | 1.33 |
|
| Protara Therapeutics Com Stk (TARA) | 0.0 | $908k | 290k | 3.13 |
|
|
| Pear Therapeutics (PEAR) | 0.0 | $230k | 901k | 0.26 |
|
|
| Motus Gi Hldgs Com New (MOTS) | 0.0 | $88k | 90k | 0.97 |
|
|
| Eqrx *w Exp 12/17/202 (EQRXW) | 0.0 | $43k | 250k | 0.17 |
|
|
| Caremax *w Exp 06/08/202 (CMAXW) | 0.0 | $29k | 60k | 0.48 |
|
|
| Surrozen *w Exp 08/01/203 (SRZNW) | 0.0 | $17k | 167k | 0.10 |
|
Past Filings by Perceptive Advisors
SEC 13F filings are viewable for Perceptive Advisors going back to 2010
- Perceptive Advisors 2023 Q1 restated filed May 16, 2023
- Perceptive Advisors 2023 Q1 filed May 15, 2023
- Perceptive Advisors 2022 Q4 filed Feb. 14, 2023
- Perceptive Advisors 2022 Q3 filed Nov. 14, 2022
- Perceptive Advisors 2022 Q2 filed Aug. 15, 2022
- Perceptive Advisors 2022 Q1 filed May 16, 2022
- Perceptive Advisors 2021 Q4 amended filed May 4, 2022
- Perceptive Advisors 2021 Q4 restated filed April 13, 2022
- Perceptive Advisors 2021 Q4 filed Feb. 14, 2022
- Perceptive Advisors 2021 Q3 restated filed Dec. 3, 2021
- Perceptive Advisors 2021 Q3 filed Nov. 15, 2021
- Perceptive Advisors 2021 Q2 amended filed Aug. 17, 2021
- Perceptive Advisors 2021 Q2 filed Aug. 16, 2021
- Perceptive Advisors 2021 Q1 restated filed Aug. 13, 2021
- Perceptive Advisors 2021 Q1 amended filed June 10, 2021
- Perceptive Advisors 2021 Q1 filed May 17, 2021